Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI in Metastatic Biliary Tract Cancer
NCT03110510Phase 2Withdrawn
- Sponsor
- Samsung Medical Center
- Start
- Sep 2019
- Primary completion
- Sep 2019
- Modality
- Nanoparticles, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, folinic acid in biliary tract cancer (BTC), sponsored by Samsung Medical Center. Planned start Sep 2019; status: withdrawn.
02
Drugs
fluorouracilirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfolinic acid
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03110510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110510.